Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of Rejuveinix in Combination With Standard Interventional Therapy for Critical Limb Ischemia Patients

NCT03041259 is registered in ClinicalTrials.gov with Reven Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03041259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03041259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Dose-Escalation Study Evaluating the Safety, Tolerability and Efficacy of Rejuveinix in Combination With Standard Interventional Therapy for Critical Limb Ischemia Patients
Lead sponsor
Reven Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 31, 2020
Completion date
July 31, 2022
Enrollment
320 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

critical limb ischemia, peripheral arterial disease